A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, antibiotics and other drugs to manage the sometimes debilitating symptoms. However, ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Therapies to treat IPF are limited ... and cellular interactions in distinct cell populations in chronic obstructive pulmonary disease ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...

For the first time Australian researchers have identified how exposure to smoking may cause a deadly lung disease that claims ...

In their study, the researchers looked at the effects of cigarette smoke on Mucosal-Associated Invariant T (MAIT) cells, a ...